NCT04710043 - Dose Escalation Trial of BNT152+153 in Patients With Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

September 10, 2025

Study Completion Date

September 10, 2025

Conditions

Solid Tumor

Interventions

DRUG

BNT152

intravenous

DRUG

BNT153

intravenous

Trial Locations (7)

Duke Cancer Center, Durham

Sarah Cannon Research Institute at Tennessee Oncology, Nashville

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago

Masaryk Memorial Cancer Institute, Brno

MD Anderson Cancer Center, Houston

NEXT Oncology, San Antonio

Yale Cancer Center, New Haven